PHARMAC is seeking feedback on a proposal to fund 2 new treatments for type 2 diabetes:
- empagliflozin (Jardiance) and empagliflozin with metformin (Jardiamet) supplied by Boehringer Ingelheim, with funding to start from 1 December 2020
- dulaglutide (Trulicity) supplied by Eli Lilly, with funding to start as soon as practicable following Medsafe approval.
The funding of both treatments would be restricted to people with type 2 diabetes who are at high risk of heart and kidney complications.
This proposal also includes changes to the price and contractual arrangements with Novartis for vildagliptin (Galvus) and vildagliptin with metformin (Galvumet) from 1 December 2020. These treatments would continue to be funded without restrictions.
Consultation closes at 4pm Friday 2 October 2020 and feedback can be emailed to firstname.lastname@example.org. Find further details on this proposal, including how to provide feedback.
Proposal to fund two new medicines for type 2 diabetes PHARMAC, 9 September 2020